CTOs on the Move


 
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.dsm.com
  • 45 Waterview Blvd
    Parsippany, NJ USA 07054
  • Phone: 973.257.8500

Executives

Name Title Contact Details
Frederic Dross
Vice President of Technology Americas Profile

Similar Companies

Aldeyra Therapeutics, Inc

Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to begin clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.

Five Prime Therapeutics

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company`s product candidates include FP-1039/GSK3052230, a protein therapeutic is in PhaseIb clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, an antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumors. It has collaboration and license agreements with GlaxoSmithKline LLC, Glaxo Group Limited, GSK-HGS, Pfizer Inc., and UCB Pharma S.A. The company was founded in 2001 and is headquartered in South San Francisco, California.

Stellar Biotechnologies

Stellar Biotechnologies is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimers, and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

Numira

Numira is a specialty preclinical CRO that combines innovative technologies and expertise to provide unique solutions to a wide variety of preclinical drug discovery efforts.   We support leading pharmaceutical, biotech, and medical device companies in the areas of discovery research and efficacy evaluation, offering services in the following areas - High-Resolution MicroCT Imaging, Image Analysis (microCT, MRI, ECG, histology data), Specialized Histology (GLP or non-GLP), 3D Oncology Cell Screening.   Utilizing our patented imaging reagents and powerful 3D visualization and analytic tools, we provide images, metrics, and analyses that will allow definitive answers much more rapidly and accurately than ever before, saving your team valuable time and resources.

BioHarp UNI US

BioHarp UNI US is a Sun Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.